DiagnoCure grants Gen-Probe rights to prostate cancer test
Executive Summary
Gen-Probe (nucleic acid tests) is speeding its entry into the oncology screening market by licensing exclusive worldwide rights to DiagnoCure's (cancer detection) highly specific genetic marker for prostate cancer.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Urine-based Testing
Deal Status
- Concluded
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice